GLENMARK PHARMA S
Can Zaynich do for Wockhardt what Ozempic did for Novo Nordisk?
Wockhardt's Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk's Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.
Ozempic frenzy lures rich Indians to brave the gray market
People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage, fueling a high demand. According to Goldman Sachs Research, the anti-obesity medication market could hit $100 billion by 2030. In contrast, Indians have largely been observers in this global frenzy over the new weight-loss solutions.
Expert panel to soon weigh plan to use generics for prescription drugs
An expert committee is set to discuss the feasibility of allowing generic substitutions for prescription drugs in India. The proposal has sparked a disagreement between the Indian Pharmaceutical Alliance (IPA) and the All India Drug Action Network (AIDAN). The IPA opposes the idea, arguing that it would lead to a surge of demand from trade channels, such as general pharmacy stores, which would not benefit patients.
F&O stocks: SBI Life, Glenmark Pharma among 5 stocks with short buildup
SBI Life, Glenmark Pharma, and IOC were among the 5 stocks with a buildup of fresh short positions. Friday's trading session saw these stocks witnessing a rise in open interest as their prices declined.
Ahead of June 4, be relatively light & in cash; curtail trading: Dipan Mehta
Dipan Mehta advises caution and light trading ahead of the upcoming election dates. He emphasizes the importance of being in cash and watching the election results closely for investment decisions.
Pharma an undervalued, under-owned, high on comfort space for next 1-2 years: N Jayakumar
I think the market is not necessarily differentiated between consumption in the rural or consumption in the urban space. I think in general, consumption stocks have been lacklustre, languid if you will, but I think large scale recoveries in the market have happened across the board.
Torrent Pharma, Glenmark Pharma shares jump up to 9% after Q4 results
Shares of Torrent Pharma and Glenmark Pharma surged post Q4 results. Torrent Pharma's net profit jumped 56% YoY while Glenmark Pharma reported increased losses. Motilal Oswal provides target prices for both companies.
Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoY
Glenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss of Rs 34.5 crore in the corresponding quarter of the previous year. In FY24, Glenmark's consolidated revenue reached Rs. 11,813 crore, a 2% increase year-over-year. The company's EBITDA margin for the fiscal year was 10.1%, primarily due to a one-time impact on sales in the India business during the third quarter.
Buy the dip in UPL; go long on Hindalco, says Vishal Malkan
Vishal Malkan analyzes the market's strong bottom at 22,000, recommends Tata Power, Sun Pharma, Glenmark stocks. Malkan further favours Ashok Leyland while suggesting UPL as a buy on dip. Metals showing strength, with Hindalco poised for gains. There is a very strong support for Hindalco at around 610-615 which was a resistance earlier. With that stop loss, one can go long for targets of 690 and 700 plus.
F&O stocks: Godrej Consumer Products, Cipla among 5 stocks with short buildup
In Tuesday's trading session, the following five stocks witnessed a build of fresh short positions. Let us first understand how this conclusion is reached that whether the stock has seen a buildup of fresh short position or not.
Glenmark Pharma gets USFDA nod for generic anti-inflammatory drug
Glenmark Pharmaceuticals received USFDA approval for generic Acetaminophen and Ibuprofen tablets. The product, a version of Advil Dual Action, will be distributed by Glenmark Therapeutics Inc, USA. Advil Dual Action achieved annual sales of around USD 84.1 million. Glenmark has 195 products authorized for distribution and 52 ANDAs pending approval.
Delhi HC upholds injunction against Glenmark Pharma
Sun Pharma Laboratories, a wholly-owned subsidiary of Sun Pharmaceutical Industries, and Glenmark are contesting over their right to use drug names “Istamet” and “Indamet”, respectively, which Sun Pharma finds to be deceptively similar and confusing.
Pharma, healthcare top bets of fund managers in March
They also purchased insurance stocks like SBI Life, HDFC Life, and ICICI Prudential Life Insurance after favourable guidelines on the surrender value of policies were announced by the insurance regulator IRDAI. Also, the recent removal of the age limit on availing of health insurance is seen as boosting the prospects of life insurance companies.
Relief for pharma companies as API prices see a sharp fall
India's pharmaceutical industry, which is dependent on China for APIs, intermediates and bulk drugs, had seen an exponential price increase during Covid times. The rise in API prices continued until early this year. However, things have started to change, people in the know told ET.
Delhi High Court seeks response from govt, NPPA on Glenmark's plea
Delhi High Court hears Glenmark Pharma's petition against NPPA's pricing order for anti-diabetic drugs, claiming arbitrary pricing and seeking exemption due to DCGI approval.
Pharma stock set to rise 6%, realty player eyes 7% gain
Nifty saw a stronger-than-expected start to the session but gradually gave up its gains. It still closed with a modest gain.
PLI schemes attract over Rs 1.06 lakh crore investment till Dec; pharma sector gets major chunk
PLI schemes across sectors attracted significant investments by December 2023, notably in pharma and solar industries. While some sectors thrived, others like IT hardware, auto, and textiles faced tepid interest, prompting a review for scheme improvements.
Pharma raw material makers in race to tank up on CXO talent
Some of these PE-owned platform companies include Advent International-led Cohance Lifesciences / Suven Pharma, PAG and CX Partners-funded Sekhmet Pharmaventures, and Carlyle-backed Viyash Lifesciences and Sequent Scientific (animal API manufacturer).
F&O stocks: Trent, Glenmark Pharma among 5 stocks with short buildup
Coming to the buildup of fresh short positions, when the stock prices move downward and open interest on the counter increases, it is taken as a sign of a short build-up.
Load More
